TGF-β: A novel predictor and target for anti-PD-1/PD-L1 therapy
Transforming growth factor-β (TGF-β) signaling regulates multiple physiological processes, such as cell proliferation, differentiation, immune homeostasis, and wound healing. Besides, TGF-β plays a vital role in diseases, including cancer. Accumulating evidence indicates that TGF-β controls the comp...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-12-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.1061394/full |
| _version_ | 1797980157774921728 |
|---|---|
| author | Ming Yi Ming Yi Tianye Li Mengke Niu Yuze Wu Zhenyu Zhao Kongming Wu |
| author_facet | Ming Yi Ming Yi Tianye Li Mengke Niu Yuze Wu Zhenyu Zhao Kongming Wu |
| author_sort | Ming Yi |
| collection | DOAJ |
| description | Transforming growth factor-β (TGF-β) signaling regulates multiple physiological processes, such as cell proliferation, differentiation, immune homeostasis, and wound healing. Besides, TGF-β plays a vital role in diseases, including cancer. Accumulating evidence indicates that TGF-β controls the composition and behavior of immune components in the tumor microenvironment (TME). Advanced cancers leverage TGF-β to reshape the TME and escape immune surveillance. TGF-β-mediated immune evasion is an unfavorable factor for cancer immunotherapy, especially immune checkpoint inhibitors (ICI). Numerous preclinical and clinical studies have demonstrated that hyperactive TGF-β signaling is closely associated with ICI resistance. It has been validated that TGF-β blockade synergizes with ICI and overcomes treatment resistance. TGF-β-targeted therapies, including trap and bispecific antibodies, have shown immense potential for cancer immunotherapy. In this review, we summarized the predictive value of TGF-β signaling and the prospects of TGF-β-targeted therapies for cancer immunotherapy. |
| first_indexed | 2024-04-11T05:49:51Z |
| format | Article |
| id | doaj.art-7bd4eb4875d14c9cb1a2d828db9c399f |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-11T05:49:51Z |
| publishDate | 2022-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-7bd4eb4875d14c9cb1a2d828db9c399f2022-12-22T04:42:05ZengFrontiers Media S.A.Frontiers in Immunology1664-32242022-12-011310.3389/fimmu.2022.10613941061394TGF-β: A novel predictor and target for anti-PD-1/PD-L1 therapyMing Yi0Ming Yi1Tianye Li2Mengke Niu3Yuze Wu4Zhenyu Zhao5Kongming Wu6Department of Oncology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaDepartment of Breast Surgery, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, ChinaDepartment of Gynecology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, ChinaDepartment of Oncology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaDepartment of Oncology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaDepartment of Urology, Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaDepartment of Oncology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaTransforming growth factor-β (TGF-β) signaling regulates multiple physiological processes, such as cell proliferation, differentiation, immune homeostasis, and wound healing. Besides, TGF-β plays a vital role in diseases, including cancer. Accumulating evidence indicates that TGF-β controls the composition and behavior of immune components in the tumor microenvironment (TME). Advanced cancers leverage TGF-β to reshape the TME and escape immune surveillance. TGF-β-mediated immune evasion is an unfavorable factor for cancer immunotherapy, especially immune checkpoint inhibitors (ICI). Numerous preclinical and clinical studies have demonstrated that hyperactive TGF-β signaling is closely associated with ICI resistance. It has been validated that TGF-β blockade synergizes with ICI and overcomes treatment resistance. TGF-β-targeted therapies, including trap and bispecific antibodies, have shown immense potential for cancer immunotherapy. In this review, we summarized the predictive value of TGF-β signaling and the prospects of TGF-β-targeted therapies for cancer immunotherapy.https://www.frontiersin.org/articles/10.3389/fimmu.2022.1061394/fullcancer biotherapycancer immunotherapytumor microenvironmentTGF-βPD-1PD-L1 |
| spellingShingle | Ming Yi Ming Yi Tianye Li Mengke Niu Yuze Wu Zhenyu Zhao Kongming Wu TGF-β: A novel predictor and target for anti-PD-1/PD-L1 therapy Frontiers in Immunology cancer biotherapy cancer immunotherapy tumor microenvironment TGF-β PD-1 PD-L1 |
| title | TGF-β: A novel predictor and target for anti-PD-1/PD-L1 therapy |
| title_full | TGF-β: A novel predictor and target for anti-PD-1/PD-L1 therapy |
| title_fullStr | TGF-β: A novel predictor and target for anti-PD-1/PD-L1 therapy |
| title_full_unstemmed | TGF-β: A novel predictor and target for anti-PD-1/PD-L1 therapy |
| title_short | TGF-β: A novel predictor and target for anti-PD-1/PD-L1 therapy |
| title_sort | tgf β a novel predictor and target for anti pd 1 pd l1 therapy |
| topic | cancer biotherapy cancer immunotherapy tumor microenvironment TGF-β PD-1 PD-L1 |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2022.1061394/full |
| work_keys_str_mv | AT mingyi tgfbanovelpredictorandtargetforantipd1pdl1therapy AT mingyi tgfbanovelpredictorandtargetforantipd1pdl1therapy AT tianyeli tgfbanovelpredictorandtargetforantipd1pdl1therapy AT mengkeniu tgfbanovelpredictorandtargetforantipd1pdl1therapy AT yuzewu tgfbanovelpredictorandtargetforantipd1pdl1therapy AT zhenyuzhao tgfbanovelpredictorandtargetforantipd1pdl1therapy AT kongmingwu tgfbanovelpredictorandtargetforantipd1pdl1therapy |